stockportfolio.pro
MiniMed Group, Inc. (MMED)
Healthcare · Medical Instruments & Supplies · NasdaqGS
MiniMed Group, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $2.25B | $2.47B | $2.71B |
| Gross profit | $1.31B | $1.44B | $1.52B |
| Net income | $-96.00M | $-112.00M | $-250.00M |
| Net margin | -4.3% | -4.5% | -9.2% |
Source: MiniMed Group, Inc. SEC filings (10-K).
Explore 3 years of MiniMed Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MMED in your portfolio →
MiniMed Group, Inc. financial history by metric
About MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
MiniMed Group, Inc. — frequently asked questions
What is MiniMed Group, Inc.'s revenue?
MiniMed Group, Inc. (MMED) reported revenue of $2.71B for fiscal year 2025, up 10.0% from the prior year, according to its SEC filings.
Is MiniMed Group, Inc. profitable?
No — MMED reported a net loss of $-250.00M in fiscal 2025.
What is MMED's P/E ratio?
MiniMed Group, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is MiniMed Group, Inc. growing?
MMED's revenue grew at roughly 10.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does MiniMed Group, Inc. have?
As of fiscal year 2025, MMED carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MiniMed Group, Inc.'s gross margin?
MMED's gross margin was 56.2% in fiscal 2025 — gross profit of $1.52B on revenue of $2.71B.
What is MiniMed Group, Inc.'s market cap?
MiniMed Group, Inc. (MMED) has a market capitalization of about $4.26B, based on the latest data in our nightly-refreshed cache.
When does MiniMed Group, Inc.'s fiscal year end?
MMED's fiscal year ends in April. Its most recent annual filing covers the fiscal year ending 2025-04-30.
Where does this data come from?
All figures are computed from MiniMed Group, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.